Hennion & Walsh Asset Management, Inc. Mirum Pharmaceuticals, Inc. Call Options Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.1 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding MIRM
# of Institutions
211Shares Held
53.8MCall Options Held
2.6KPut Options Held
99.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.57MShares$285 Million16.29% of portfolio
-
Janus Henderson Group PLC London, X04.58MShares$199 Million0.1% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$141 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.8MShares$121 Million4.33% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.61MShares$113 Million2.07% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.6B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...